Latest Insider Transactions at Amylyx Pharmaceuticals, Inc. (AMLX)
This section provides a real-time view of insider transactions for Amylyx Pharmaceuticals, Inc. (AMLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Amylyx Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Amylyx Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,421
-3.77%
|
$27,105
$5.54 P/Share
|
|
Nov 04
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,690
+1.96%
|
$63,690
$1.57 P/Share
|
|
Sep 30
2024
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,442
-7.37%
|
$34,326
$3.2 P/Share
|
|
Sep 30
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,589
-0.57%
|
$55,767
$3.2 P/Share
|
|
Sep 30
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,589
-0.59%
|
$55,767
$3.2 P/Share
|
|
Sep 30
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,709
-5.75%
|
$26,127
$3.2 P/Share
|
|
Sep 23
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,857
+0.06%
|
$1,857
$1.57 P/Share
|
|
Sep 12
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,449
+1.05%
|
$34,449
$1.57 P/Share
|
|
Sep 12
2024
|
James M Frates Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+14.63%
|
$80,000
$2.53 P/Share
|
|
Sep 05
2024
|
Karen Firestone |
BUY
Open market or private purchase
|
Direct |
50,000
+47.62%
|
$100,000
$2.13 P/Share
|
|
Sep 03
2024
|
George M Milne Jr |
BUY
Open market or private purchase
|
Direct |
100,000
+10.43%
|
$200,000
$2.2 P/Share
|
|
May 15
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,455
-6.46%
|
$10,455
$1.88 P/Share
|
|
May 15
2024
|
Daphne Quimi |
BUY
Open market or private purchase
|
Direct |
2,250
+31.03%
|
$2,250
$1.89 P/Share
|
|
May 14
2024
|
Daphne Quimi |
BUY
Open market or private purchase
|
Direct |
2,750
+50.0%
|
$2,750
$1.88 P/Share
|
|
Apr 16
2024
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,910
+38.43%
|
-
|
|
Apr 16
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
179,850
+5.42%
|
-
|
|
Apr 16
2024
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,560
+33.22%
|
-
|
|
Apr 16
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
179,850
+5.32%
|
-
|
|
Apr 16
2024
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
91,180
+28.75%
|
-
|
|
Mar 05
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,540
-1.86%
|
$27,720
$18.73 P/Share
|
|
Mar 05
2024
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,792
-1.31%
|
$32,256
$18.73 P/Share
|
|
Mar 05
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,135
-0.14%
|
$74,430
$18.73 P/Share
|
|
Mar 05
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,135
-0.14%
|
$74,430
$18.73 P/Share
|
|
Feb 26
2024
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+20.83%
|
-
|
|
Feb 26
2024
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+4.1%
|
-
|
|
Feb 26
2024
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+4.02%
|
-
|
|
Feb 26
2024
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,667
+30.66%
|
-
|
|
Feb 23
2024
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,838
-5.78%
|
$51,084
$18.76 P/Share
|
|
Jan 25
2024
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
9,100
-1.19%
|
-
|
|
Jan 16
2024
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
94,350
-10.95%
|
-
|
|
Jan 09
2024
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,841
-0.2%
|
$93,456
$16.33 P/Share
|
|
Jan 09
2024
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,716
-2.37%
|
$43,456
$16.33 P/Share
|
|
Jan 09
2024
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,841
-0.21%
|
$93,456
$16.33 P/Share
|
|
Jan 09
2024
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,812
-1.35%
|
$44,992
$16.33 P/Share
|
|
Dec 27
2023
|
Margaret Olinger Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+8.3%
|
$0
$0.37 P/Share
|
|
Dec 15
2023
|
Karen Firestone |
BUY
Open market or private purchase
|
Direct |
4,000
+44.44%
|
$56,000
$14.97 P/Share
|
|
Nov 27
2023
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,333
+50.0%
|
-
|
|
Nov 16
2023
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,694
+2.14%
|
$63,694
$1.57 P/Share
|
|
Oct 31
2023
|
James M Frates Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
11,072
+50.0%
|
-
|
|
Aug 23
2023
|
James M Frates Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,165
+14.59%
|
$108,990
$6.88 P/Share
|
|
Aug 15
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
2,000,000
-28.58%
|
-
|
|
Aug 15
2023
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,164
-11.16%
|
$123,280
$20.88 P/Share
|
|
Jul 12
2023
|
Margaret Olinger Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+7.38%
|
$0
$0.37 P/Share
|
|
May 22
2023
|
Margaret Olinger Chief Commercial Officer |
SELL
Bona fide gift
|
Direct |
1,580
-0.68%
|
-
|
|
May 17
2023
|
Gina Mazzariello Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
500
-0.9%
|
-
|
|
May 16
2023
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,500
-18.59%
|
$877,500
$27.27 P/Share
|
|
May 16
2023
|
James M Frates Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+26.93%
|
$195,000
$6.88 P/Share
|
|
May 15
2023
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,965
-5.43%
|
$346,985
$29.03 P/Share
|
|
May 15
2023
|
Patrick D Yeramian Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,965
+2.64%
|
$35,895
$3.63 P/Share
|
|
Apr 17
2023
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
49,579
-9.62%
|
$1,487,370
$30.74 P/Share
|